Telangana life sciences ecosystem reaches $145 billion valuation
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
The study was conducted by PwC India in line with ISO 14040 and ISO 14044 protocols
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
Postdoctoral fellowship aims to build skilled talent pool in biotechnology and life sciences
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
To boost compostable packaging, resin innovation, and supply chain speed
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
The dual expansion simplifies transcriptomics workflows by combining faster regional turnaround with easier sample logistics
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The new capital is expected to fund the company through 2029
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Subscribe To Our Newsletter & Stay Updated